tiprankstipranks
Kyverna Therapeutics, Inc. (KYTX)
NASDAQ:KYTX
US Market
KYTX
Kyverna Therapeutics, Inc.
RESEARCH TOOLSreports
Want to see KYTX full AI Analyst Report?

Kyverna Therapeutics, Inc. (KYTX) Stock Forecast & Price Target

1,049 Followers
See the Price Targets and Ratings of:

KYTX Analyst Ratings

Strong Buy
4Ratings
Strong Buy
4 Buy
0 Hold
0 Sell
Based on 4 analysts giving stock ratings to
Kyverna
Therapeutics, Inc.
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

KYTX Stock 12 Month Forecast

Average Price Target

$30.33
▲(309.36% Upside)
Based on 4 Wall Street analysts offering 12 month price targets for Kyverna Therapeutics, Inc. in the last 3 months. The average price target is $30.33 with a high forecast of $33.00 and a low forecast of $25.00. The average price target represents a 309.36% change from the last price of $7.41.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","10":"$10","18":"$18","26":"$26","34":"$34"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$33.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30.333333333333332,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$30.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$25.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,10,18,26,34],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.3,9.276923076923076,11.253846153846153,13.23076923076923,15.207692307692307,17.184615384615384,19.16153846153846,21.138461538461538,23.115384615384613,25.092307692307692,27.069230769230767,29.046153846153846,31.02307692307692,{"y":33,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.3,9.071794871794872,10.843589743589742,12.615384615384615,14.387179487179488,16.15897435897436,17.93076923076923,19.702564102564104,21.474358974358974,23.246153846153845,25.017948717948716,26.78974358974359,28.56153846153846,{"y":30.333333333333332,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.3,8.661538461538461,10.023076923076923,11.384615384615383,12.746153846153845,14.107692307692307,15.46923076923077,16.83076923076923,18.192307692307693,19.553846153846155,20.915384615384617,22.276923076923076,23.638461538461538,{"y":25,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.44,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.59,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.97,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.97,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.73,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.4,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.33,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.51,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.77,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.87,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.22,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.44,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.3,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$33.00Average Price Target$30.33Lowest Price Target$25.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wells Fargo Analyst forecast on KYTX
Derek Archila
Wells Fargo
Wells Fargo
$33
Buy
345.34%
Upside
Reiterated
08/14/26
Analysts Offer Insights on Healthcare Companies: Kyverna Therapeutics, Inc. (NASDAQ: KYTX) and ArriVent BioPharma, Inc. (NASDAQ: AVBP)
William Blair Analyst forecast on KYTX
Sami Corwin
William Blair
William Blair
―
Buy
―
Reiterated
08/12/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Tecan Group AG (Other OTC: TCHBF), Kyverna Therapeutics, Inc. (NASDAQ: KYTX) and Pliant Therapeutics (NASDAQ: PLRX)
H.C. Wainwright Analyst forecast on KYTX
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
$25
Buy
237.38%
Upside
Reiterated
08/12/26
Kyverna Therapeutics: Buy Rating Reiterated as Pipeline Progress and Strong Financial Runway Support Unchanged $25 Price Target
Morgan Stanley Analyst forecast on KYTX
Michael Ulz
Morgan Stanley
Morgan Stanley
$33
Buy
345.34%
Upside
Assigned
08/12/26
Morgan Stanley Keeps Their Buy Rating on Kyverna Therapeutics, Inc. (KYTX)
J.P. Morgan Analyst forecast on KYTX
Brian Cheng
J.P. Morgan
J.P. Morgan
$30→$29
Buy
291.36%
Upside
Assigned
05/13/26
Kyverna Therapeutics price target lowered to $29 from $30 at JPMorganKyverna Therapeutics price target lowered to $29 from $30 at JPMorgan
Leerink Partners Analyst forecast on KYTX
Thomas Smith
Leerink Partners
Leerink Partners
$25→$32
Buy
331.85%
Upside
Reiterated
12/15/25
Kyverna Therapeutics' Promising KYSA-8 Study and Strategic Plans Bolster Buy Rating
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wells Fargo Analyst forecast on KYTX
Derek Archila
Wells Fargo
Wells Fargo
$33
Buy
345.34%
Upside
Reiterated
08/14/26
Analysts Offer Insights on Healthcare Companies: Kyverna Therapeutics, Inc. (NASDAQ: KYTX) and ArriVent BioPharma, Inc. (NASDAQ: AVBP)
William Blair Analyst forecast on KYTX
Sami Corwin
William Blair
William Blair
―
Buy
―
Reiterated
08/12/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Tecan Group AG (Other OTC: TCHBF), Kyverna Therapeutics, Inc. (NASDAQ: KYTX) and Pliant Therapeutics (NASDAQ: PLRX)
H.C. Wainwright Analyst forecast on KYTX
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
$25
Buy
237.38%
Upside
Reiterated
08/12/26
Kyverna Therapeutics: Buy Rating Reiterated as Pipeline Progress and Strong Financial Runway Support Unchanged $25 Price Target
Morgan Stanley Analyst forecast on KYTX
Michael Ulz
Morgan Stanley
Morgan Stanley
$33
Buy
345.34%
Upside
Assigned
08/12/26
Morgan Stanley Keeps Their Buy Rating on Kyverna Therapeutics, Inc. (KYTX)
J.P. Morgan Analyst forecast on KYTX
Brian Cheng
J.P. Morgan
J.P. Morgan
$30→$29
Buy
291.36%
Upside
Assigned
05/13/26
Kyverna Therapeutics price target lowered to $29 from $30 at JPMorganKyverna Therapeutics price target lowered to $29 from $30 at JPMorgan
Leerink Partners Analyst forecast on KYTX
Thomas Smith
Leerink Partners
Leerink Partners
$25→$32
Buy
331.85%
Upside
Reiterated
12/15/25
Kyverna Therapeutics' Promising KYSA-8 Study and Strategic Plans Bolster Buy Rating
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
BTSGBrightSpring Health Services, Inc.
AMLXAmylyx Pharmaceuticals Inc
IMMXImmix Biopharma
JBIOJade Biosciences
GHRSGH Research
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Kyverna Therapeutics, Inc.

3 Months
Michael UlzMorgan Stanley
Success Rate
10/20 ratings generated profit
50%
Average Return
-4.02%
Copying Michael Ulz's trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of -4.02% per trade.
1 Year
Michael UlzMorgan Stanley
Success Rate
12/20 ratings generated profit
60%
Average Return
+35.94%
Copying Michael Ulz's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +35.94% per trade.
2 Years
Michael UlzMorgan Stanley
Success Rate
14/20 ratings generated profit
70%
Average Return
+41.37%
Copying Michael Ulz's trades and holding each position for 2 Years would result in 70.00% of your transactions generating a profit, with an average return of +41.37% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

KYTX Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
5
10
9
8
6
Buy
2
3
3
3
3
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
7
13
12
11
9
In the current month, KYTX has received 9 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. KYTX average Analyst price target in the past 3 months is 30.33.
Each month's total comprises the sum of three months' worth of ratings.

KYTX Financial Forecast

KYTX Earnings Forecast

Next quarter’s earnings estimate for KYTX is -$0.69 with a range of -$0.77 to -$0.65. The previous quarter’s EPS was -$0.63. KYTX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year KYTX has Performed in-line its overall industry.
Next quarter’s earnings estimate for KYTX is -$0.69 with a range of -$0.77 to -$0.65. The previous quarter’s EPS was -$0.63. KYTX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year KYTX has Performed in-line its overall industry.
No data currently available

KYTX Sales Forecast

Next quarter’s sales forecast for KYTX is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. KYTX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year KYTX has Performed in-line its overall industry.
Next quarter’s sales forecast for KYTX is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. KYTX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year KYTX has Performed in-line its overall industry.

KYTX Stock Forecast FAQ

What is KYTX’s average 12-month price target, according to analysts?
Based on analyst ratings, Kyverna Therapeutics, Inc.’s 12-month average price target is 30.33.
    What is KYTX’s upside potential, based on the analysts’ average price target?
    Kyverna Therapeutics, Inc. has 309.36% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is KYTX a Buy, Sell or Hold?
          Kyverna Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 4 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Kyverna Therapeutics, Inc.’s price target?
            The average price target for Kyverna Therapeutics, Inc. is 30.33. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $33.00 ,the lowest forecast is $25.00. The average price target represents 309.36% Increase from the current price of $7.41.
              What do analysts say about Kyverna Therapeutics, Inc.?
              Kyverna Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.
                How can I buy shares of KYTX?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.